• May 19, 2009
  Cylene to Announce New Data on its First-In-Class Oral CK2 Inhibitor against Cancer at BIO Conference
• April 17, 2009
  Cylene to Present Advances in its Oral Inhibitor of CK2 at AACR Annual Meeting
• January 5, 2009
  Cylene Pharmaceuticals Initiates Phase I Trial with CX-4945 – Breakthrough First-in Class Inhibitor of CK2
• January 1, 2009
  Cylene Pharmaceuticals Promotes John K.C. Lim, Pharm.D. and David M. Ryckman, Ph.D. to Senior Vice Presidents
• December 15, 2008
  Cylene Pharmaceuticals Initiates Phase II Clinical Trial of Quarfloxin (CX-3543) in Patients with Carcinoid/Neuroendocrine Tumors
• March 14, 2008
  Cylene Pharmaceuticals Promotes Claire S. Padgett to Vice President of Clinical Operations
• January 28, 2008
  Cylene Pharmaceuticals Appoints Kenna Anderes, Ph.D. as Vice President of Cancer Biology
• July 10, 2007
  Cylene Pharmaceuticals Appoints David M. Ryckman, Ph.D. as Vice President of Manufacturing and Pharmaceutical Operations
• June 28, 2007
  Cylene Pharmaceuticals’ Ribosomal RNA Biogenesis Inhibitor, Quarfloxin (CX-3543), Enters Phase II Clinical Trial
• June 25, 2007
  2007 ASCO Presentation
• January 31, 2007
  Cylene Announces Issuance of Additional U.S. Patents Covering Lead Compound CX-3543, Strengthening Cylene’s Intellectual Property Position in rRNA Biogenesis Inhibition
• January 23, 2007
  Cylene Pharmaceuticals Closes $44 Million Series C Financing